World Wellness Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Wellness Times.

Press releases published on September 22, 2026

Sep. 22, 2026

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker

Indeterminate GlobeNewswire

Sep. 22, 2026

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

Indeterminate GlobeNewswire

Sep. 22, 2026

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Indeterminate GlobeNewswire

Sep. 22, 2026

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Indeterminate GlobeNewswire

Sep. 22, 2026

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Indeterminate GlobeNewswire

Sep. 22, 2026

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Indeterminate GlobeNewswire

Sep. 22, 2026

Elevar Therapeutics Receives FDA Conditional Acceptance of LYRFIGTU as Brand Name for Lirafugratinib

Indeterminate GlobeNewswire

Sep. 22, 2026

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

Indeterminate GlobeNewswire

Sep. 22, 2026

Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium

Indeterminate GlobeNewswire

Sep. 22, 2026

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

Indeterminate GlobeNewswire

Sep. 22, 2026

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Indeterminate GlobeNewswire

Sep. 22, 2026

The Trillion-Dollar Buildout Lands in Las Vegas: Yotta 2026 Opens Next Week

Indeterminate GlobeNewswire

Sep. 22, 2026

Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

Indeterminate GlobeNewswire

Sep. 22, 2026

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Indeterminate GlobeNewswire

Sep. 22, 2026

Clene to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 22, 2026

Medera Expands Singapore Presence Through Partnership with National Heart Centre Singapore

Indeterminate GlobeNewswire

Sep. 22, 2026

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Indeterminate GlobeNewswire

Sep. 22, 2026

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Indeterminate GlobeNewswire

Sep. 22, 2026

Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase

Indeterminate GlobeNewswire

Sep. 22, 2026

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

Indeterminate GlobeNewswire